In cancer treatment, the combination of the FMD with chemotherapy in mice delayed the progression of breast cancer and melanoma by increasing the number of bone marrow common lymphoid progenitor cells and cytotoxic CD8+ tumor-infiltrating lymphocytes and, at least in a mouse breast cancer model, the downregulation of the stress-responsive enzyme heme oxygenase-1 (102). Here, HMOX1 is linked to breast cancer.